Breaking Down Biologic Therapies in Moderate to Severe Atopic Dermatitis: Who, What, When, Why, and How?

CE Information

1.0 CE credit

Completion Time

1 hour

Available Until

December 1, 2025

Posted By

PCE

Ready to start this activity?

Navigate

Overview

Specialties

Adult, Family, Pediatric, and Women's Health

Subspecialties

Allergy/Immunology, Dermatology, and Primary Care

Clinical Topics

Dermatologic Disease

Watch an on-demand webcast of expert faculty presentation on the pathophysiology of and available biologic therapeutics for treating moderate to severe atopic dermatitis.

Learning Objectives

Upon completion of this activity, participants should be able to:

Evaluate the medical need, clinical rationale, and available clinical evidence on emerging biologic therapies for patients with moderate to severe AD
Identify all patient candidates for available and emerging biologic therapies for moderate to severe AD
Integrate recommended disease assessment measures into treatment advancement approaches for patients with moderate to severe AD

Speakers

Sandri Johnson MSN, FNP-BC, DCNP

Dermatology Nurse Practitioner
Midtown Dermatology
Raleigh and Rocky Mount, North Carolina

Jonathan Silverberg MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

CE Information

This activity offers 1.0 CE credit to attendees.

Accredited by AAPA, ANCC, IPCE.

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

Nurse Practitioners: 1.00 Nursing contact hours, includes 1.00 hour of pharmacotherapy credit

Disclosures

PACE requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to PACE policies. Others involved in the planning of this activity have no relevant financial relationships.

Primary Author

Sandri Johnson, MSN, FNP-BC, DCNP

Dermatology Nurse Practitioner
Midtown Dermatology
Raleigh and Rocky Mount, North Carolina

Sandri Johnson, MSN, FNP-BC, DCNP: consultant/advisor/speaker: AbbVie, Amgen, Arcutis, Bristol Myers Squibb, Dermavant, Galderma, Leo, Lilly, Sanofi/Regeneron, UCB; other financial or material support: Johnson & Johnson.

Jonathan Silverberg, MD, PhD, MPH

Professor
Director of Clinical Research
Director of Patch Testing
George Washington University School of Medicine and Health Sciences
Washington, DC

Jonathan Silverberg, MD, PhD, MPH: consultant/advisor/speaker: AbbVie, Alamar, Aldena, Amgen, AOBiome, Apollo, Arcutis, Arena, Asana, Aslan, Attovia, BiomX, Biosion, Bodewell, Boehringer Ingelheim, Bristol Myers Squibb, Cara, Castle Biosciences, Celgene, Connect Biopharma, CorEvitas, Dermavant, FIDE, Galderma, GlaxoSmithKline, Incyte, Inmagene, Invea, Kiniksa, Leo Pharma, Lilly, Merck, MyOr Diagnostics, Nektar, Novartis, Optum, Pfizer, RAPT, Recludix, Regeneron, Sandoz, Sanofi/Genzyme, Shaperon, Target RWE, Teva, Union.

Kristine Kucera, PA-C, MPAS, DHS: consultant/advisor/speaker: AbbVie, Amgen, Arcutis, Beiersdorf, Bristol-Myers Squibb, Janssen, Leo Pharma, Novartis, Sun Pharma, UCB.

Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Back to navigate